1-20 of 26
Peter J. Houghton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma

Available to Purchase
Terry J. Shackleford, Seethalakshmi Hariharan, Angelina V. Vaseva, Karina Alagoa, Maricruz Espinoza, Hemant K. Bid, Fuyang Li, Haihong Zhong, Doris A. Phelps, Ryan D. Roberts, Hakan Cam, Cheryl A. London, Denis C. Guttridge, Yidong Chen, Manjeet Rao, Yuzuru Shiio, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (4): 539–550.
https://doi.org/10.1158/1535-7163.MCT-20-0625
Published: 03 April 2023
View articletitled, Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma
Open the PDF for Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma in another window
Includes: Supplementary data
Journal Articles

Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma

Available to Purchase
Nicole R. Hensch, Kathryn Bondra, Long Wang, Prethish Sreenivas, Xiang R. Zhao, Paulomi Modi, Angelina V. Vaseva, Peter J. Houghton, Myron S. Ignatius
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (1): 123–134.
https://doi.org/10.1158/1535-7163.MCT-22-0310
Published: 03 January 2023
View articletitled, Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma
Open the PDF for Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium

Available to Purchase
Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang, Michael E. Roth, Yifei Wang, Jonathan B. Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory Gatto, Edward A. Kolb, Malcolm A. Smith, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (8): 1318–1325.
https://doi.org/10.1158/1535-7163.MCT-21-0758
Published: 02 August 2022
View articletitled, Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium
Open the PDF for Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium in another window
Journal Articles

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Open Access
Yifei Wang, Xiangjun Tian, Wendong Zhang, Zhongting Zhang, Rossana Lazcano, Pooja Hingorani, Michael E. Roth, Jonathan D. Gill, Douglas J. Harrison, Zhaohui Xu, Sylvester Jusu, Sankaranarayanan Kannan, Jing Wang, Alexander J. Lazar, Eric J. Earley, Stephen W. Erickson, Tara Gelb, Philip Huxley, Johanna Lahdenranta, Gemma Mudd, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 903–913.
https://doi.org/10.1158/1535-7163.MCT-21-0836
Published: 01 June 2022
View articletitled, Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Open the PDF for Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma in another window
Includes: Supplementary data
Journal Articles

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Available to Purchase
Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman, Cody J. Peer, William D. Figg, Myron S. Ignatius, Kris C. Wood, Peter J. Houghton, Angelina V. Vaseva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 170–183.
https://doi.org/10.1158/1535-7163.MCT-21-0194
Published: 07 January 2022
View articletitled, Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Open the PDF for Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma in another window
Includes: Supplementary data
Journal Articles

International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer

Open Access
Gilles Vassal, Peter J. Houghton, Stefan M. Pfister, Malcolm A. Smith, Huib N. Caron, Xiao-Nan Li, David J. Shields, Olaf Witt, Jan J. Molenaar, Sara Colombetti, Julia Schüler, Lou F. Stancato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1462–1468.
https://doi.org/10.1158/1535-7163.MCT-20-0394
Published: 01 August 2021
View articletitled, International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Open the PDF for International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C001: Prospective use of the single mouse experimental design for evaluation of PLX038A against pediatric solid tumor models

Free
Samson Ghilu, Qilin Li, Shaun D Fontaine, Daniel V. Santi, Raushan T. Kurmasheva, Siyuan Zheng, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C001.
https://doi.org/10.1158/1535-7163.TARG-19-C001
Published: 01 December 2019
View articletitled, Abstract C001: Prospective use of the single mouse experimental design for evaluation of PLX038A against pediatric solid tumor models
Journal Articles

Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Free
Raushan Kurmasheva, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, John M. Maris, Yael P. Mosse, Kateryna Krytska, David Groff, Matthew Tang, Yifei Wang, Brad St. Croix, Richard Gorlick, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C003.
https://doi.org/10.1158/1535-7163.TARG-19-C003
Published: 01 December 2019
View articletitled, Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)
Journal Articles

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Free
Kristina A. Cole, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Min Kang, C. Patrick Reynolds, Xiao-Nan Li, Holly Lindsay, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B13.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B13
Published: 01 January 2018
View articletitled, Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib
Journal Articles

Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Free
Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B15.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B15
Published: 01 January 2018
View articletitled, Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan
Journal Articles

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Free
Beverly A. Teicher, Richard B. Lock, Jerry M. Collins, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Raushan T. Kurmasheva, Xiao-Nan Li, Stephen W. Erickson, Yuelong Guo, Kathryn Evans, Lin Qi, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B12
Published: 01 January 2018
View articletitled, Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)
Journal Articles

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

Free
Hemant K. Bid, Doris A. Phelps, Linlin Xaio, Denis C. Guttridge, Jiayuh Lin, Cheryl London, Laurence H. Baker, Xiaokui Mo, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 1018–1028.
https://doi.org/10.1158/1535-7163.MCT-15-0567
Published: 05 May 2016
View articletitled, The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Open the PDF for The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma in another window
Includes: Supplementary data
Journal Articles

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Free
Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, Keith C.S. Sia, Hernan Carol, I-Ming Chen, Kathryn Evans, Philipp A. Dietrich, Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-14-0647
Published: 09 February 2015
View articletitled, Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Open the PDF for Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

Free
Hemant K. Bid, Ryan D. Roberts, Parmeet K. Manchanda, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (10): 1925–1934.
https://doi.org/10.1158/1535-7163.MCT-13-0164
Published: 07 October 2013
View articletitled, RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis
Open the PDF for RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis in another window
Journal Articles

Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

Free
Hemant K. Bid, Jun Zhan, Doris A. Phelps, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 649–659.
https://doi.org/10.1158/1535-7163.MCT-11-0575
Published: 06 March 2012
View articletitled, Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
Open the PDF for Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2 in another window
Includes: Supplementary data
Journal Articles

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Free
Malcolm A. Smith, Min H. Kang, Christopher Patrick Reynolds, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, John M. Maris, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C103.
https://doi.org/10.1158/1535-7163.TARG-11-C103
Published: 12 November 2011
View articletitled, Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.
Journal Articles

Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Free
Richard B. Lock, Hernan Carol, Barbara Szymanska, Ingrid Boehm, Kathryn Evans, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C107.
https://doi.org/10.1158/1535-7163.TARG-11-C107
Published: 12 November 2011
View articletitled, Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Free
C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-11-C106
Published: 12 November 2011
View articletitled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).
Journal Articles

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Free
Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C105.
https://doi.org/10.1158/1535-7163.TARG-11-C105
Published: 12 November 2011
View articletitled, Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.
Journal Articles

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Free
Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew, Andy Cooke, Yan Yao, Christine Mantis, Jennifer Kahler, Jennifer Workman, Mark Bittner, Lorina Dudkin, David M. Epstein, Neil W. Gibson, Robert Wild, Lee D. Arnold, Peter J. Houghton, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1394–1406.
https://doi.org/10.1158/1535-7163.MCT-10-1099
Published: 08 August 2011
View articletitled, Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Open the PDF for Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin in another window
Includes: Supplementary data